These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18236984)

  • 21. Response to nondipping and cardiovascular risk after morning renin–angiotensin blockade.
    Mancia G;
    Hypertension; 2013 Feb; 61(2):e16. PubMed ID: 23444461
    [No Abstract]   [Full Text] [Related]  

  • 22. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 23. Study at up to 700 sites will build on landmark HOPE trial.
    Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703
    [No Abstract]   [Full Text] [Related]  

  • 24. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 26. [Telmisartan].
    Krankenpfl J; 2005; 43(4-6):110-1. PubMed ID: 16171056
    [No Abstract]   [Full Text] [Related]  

  • 27. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE inhibitors in cardiovascular disease--unbeatable?
    McMurray JJ
    N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
    Mancia G; Parati G; Bilo G; Gao P; Fagard R; Redon J; Czuriga I; Polák M; Ribeiro JM; Sanchez R; Trimarco B; Verdecchia P; van Mieghem W; Teo K; Sleight P; Yusuf S
    Hypertension; 2012 Dec; 60(6):1400-6. PubMed ID: 23071122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Sleight P; Redon J; Verdecchia P; Mancia G; Gao P; Fagard R; Schumacher H; Weber M; Böhm M; Williams B; Pogue J; Koon T; Yusuf S;
    J Hypertens; 2009 Jul; 27(7):1360-9. PubMed ID: 19506526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
    Delles C; Raff U; Mimran A; Fauvel JP; Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 Dec; 21(12):1330-6. PubMed ID: 18989258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New clinical concepts after the ONTARGET trial.
    Ruilope LM; Segura J; Zamorano JL
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
    [No Abstract]   [Full Text] [Related]  

  • 38. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
    Zou Z; Xi GL; Yuan HB; Zhu QF; Shi XY
    J Hum Hypertens; 2009 May; 23(5):339-49. PubMed ID: 18987649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
    Schmieder RE; Delles C; Mimran A; Fauvel JP; Ruilope LM
    Diabetes Care; 2007 Jun; 30(6):1351-6. PubMed ID: 17337492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.